# Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

> **NCT06727058** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 276 (actual)

## Conditions studied

- Influenza Immunization

## Interventions

- **BIOLOGICAL:** Pandemic flu H5 mRNA vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06727058
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-09
- **Primary completion:** 2026-03-24
- **Final completion:** 2026-03-24
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06727058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06727058, "Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06727058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*